Promising drug for rare skin ulcers shows early potential
NCT ID NCT06092216
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called spesolimab in 5 adults with moderate to severe pyoderma gangrenosum, a rare autoimmune disease that causes painful skin ulcers. The goal was to see if the drug could help heal the ulcers and to understand how the body's immune system responds. The study was stopped early, but it provides initial information on how well the treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PYODERMA GANGRENOSUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for painful skin ulcers: experimental drug enters human trials
- Can a psoriasis drug heal these stubborn skin ulcers?
- New injection aims to heal skin ulcers in rare disease
- Oxygen chamber therapy put to the test for dozens of diseases
- Promising drug trial for painful skin ulcers halted early
- New wound therapy for rare skin disease shows early promise